Development and evaluation of porous membrane pellets of disopyramide phosphate for sustained release

Main Article Content

Afifa Bathool
D Vishakante Gowda
Mohammed S Khan


Aim of the present study was to prepare pellets of disopyramide phosphate (DPP) using blend of Hydroxy Propyl Methyl Cellulose (HPMC K4M) and Avicel PH 101 (Microcrystalline cellulose) and to coat the prepared pellets by mixture
of Eudragit L100 and Eudragit S100 to obtain microporous membrane for controlled release. Extrusion/spheronization method was employed to produce spherical discrete pellets of uniform size. Solid, porous, discrete, reproducible pellets were obtained. Sieve analysis data indicated that the size of prepared pellets was in the range of 850 – 1180 μm.Yield of pellets was found to be 96.5%. Prepared pellets were spherical in shape, with pores on the surface, as evidenced by scanning electron microscopy (SEM). Compatibility of the drug after encapsulation in the pellets was confirmed by DSC and by FTIR. The
prepared pellets were analyzed quantitatively for the drug content and were found to be 96.2%. In vitro drug release studies indicated F3C2 as optimized formulation. Formulation F3C2 shows 93.26% drug release up to 12 hrs. It was also observed that there was no significant release of drug in gastric pH. The release kinetics for all the formulations indicated that drug
release followed non-Fickian diffusion. In vivo study of DPP (300 mg) pellets was carried out in healthy albino rats. Plasma DPP concentrations and other pharmacokinetic parameters were statistically analyzed. The results of paired T-test for the comparison of pharmacokinetic data showed that there was no significant variation between the marketed (Norpace® CR) and F3C2. The stability studies performed on F3C2 showed no significant difference in drug content. It was concluded that the drug release performance was greatly affected by microporous membrane coating used in the preparation of pellets.


Download data is not yet available.

Article Details

How to Cite
Bathool, A., Gowda, D. V., & Khan, M. S. (2014). Development and evaluation of porous membrane pellets of disopyramide phosphate for sustained release. Asian Journal of Pharmaceutics (AJP), 6(2).


Vyas SP, Khar KR. Controlled drug delivery concepts and advances.

st ed. New Delhi: CBS Publishers; 2002. p. 1-51.

Chopra R, Alderborn G, Podczeck F, Newton JM. The influence of pellet

shape and surface properties on the drug release from uncoated and

coated pellets. Int J Pharm 2005;239:171-8.

Mothilal M, Damodharan N, Lakshmi KS, Sharanya VB, Srikrishna T.

Fomulation and in vitro evaluation of osmotic drug delivery system of

metoprolol succinate. IJPPS 2010;2,64-8.

Eckenhoff B, Theeuwes F, Urquhart J. Osmotically activated dosage

forms for rate controlled drug delivery. J Pharm Technol 1981;5:35-44.

Edavalath S, Shivanand K, Kalyani P, Prakash Rao B, Divakar G.

Formulation development and optimization of controlled porosity

osmotic pump tablets of diclofenac sodium. IJPPS 2011;3,80-7.

Gothi GD, Parikh BN, Patel TD, Patel BN, Patel CN, Patel DB. Pelletization.

JGPT 2010;2:45-57.

Patel HP, Patel JK, Ptael RR, Patel PM. Pellets: A general overview. Int J

of Pharm World Research 2010;1:1-15.

Mokler CM, van Arman CG. Pharmacology of a new antiarrhythmic

agent, ‘y-diisopropylamino-a-phenyl-a-(2-pyridyl)- butyramide-

(SC-7031). J Pharmacol Exp Ther 1962;136:114-24.

Dubetz DK, Brown NN, Hooper WD, Eadie MJ, Tyrer JH. Disopyramide

pharmacokinetics and bioavailability. Br J Clin Pharmacol 1978;6:279-81.

Hinderling PH, Garretr ER. Pharmacokinetics of the antiarrhythmic

disopyramide in healthy humans. J Pharmacokinet Biopharm


Gowda DV, Darshan J, Shivakumar HG, Siddaramaiah, Ravi V. Influence

of a microporous membrane coating on theophylline drug delivery. AJP


Takayama K, Nagai T. Novel computer optimization methodology for

pharmaceutical formulations investigated by using sustained-release

granules of indomethacin. Chem Pharm Bull (Tokyo) 1989;37:160-7.

Gattani YS, Bhagwat DA, Maske AP. Formulation and evaluation of

intragastric floating drug delivery system of diltiazem hydrochloride.

AAPS PharmSciTech 2008;2:228-31.

Chowdhary KP, Srinivasa Y. Mucoadhesive microcapsules of glipizide.

IJPS 2003;65:279-284.

Wong TW, Chan LW, Lee HY, Heng PW. Release characteristics of pectin

microspheres prepared by an emulsification technique. J Microencapsul


Vishal Gupta N, Gowda DV, Balamuralidhara V, Mohammed Khan S.

Formulation and evaluation of olanzapine matrix pellets for controlled

release. Daru 2011;19:249-56.

Yan X, Gemeinhart RA. Cisplatin delivery from Poly (acrylic

acid-co-methyl methacrylate) microparticles. J Control Release

;106:198- 208.

Radwan MA, Price JC, Tackett RL. In vitro release of disopyramide

phosphate from cellulose acetate butyrate microspheres. Drug Dev

Ind Pharm 1995;21:1453-62.

Prameela RA, Bala SC. Development of HPLC method for the

determination of olanzapine in bulk and dosage forms. IJPTR


Perumal D, Dangor CM, Alcock RS, Hurbons N, Moopanar KR. Effect

of formulation variables on in-vitro drug release and Micromeritic

properties of modified release ibuprofen microspheres. J Microencapsul


Gowda DV, Shivakumar HG. Comparative bioavailability studies of

indomethacin from two controlled release formulations in healthy

albino sheep. IJPS 2006;68:760-3.

Manjunatha M, Jagadish RL, Gowda DV, Khan MS. Preparation,

evaluation and bioavailability studies of indomethacin loaded PEA

polymeric microspheres for controlled drug delivery. Der Pharmacia

Sinica. 2010;1:141-55.

ICH Harmonized Tripartite Guidelines. Stability testing of new drug

substances and products. Q1A (R2). 2003.